Abbott Laboratories (ABT)
What's Driving Abbott's Gross Margin Growth Amid Macro Issues
ABT's gross margin hits 56.4% in Q2, fueled by Medical Devices growth, Nutrition strength, FX tailwinds and cost discipline.
Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott Gains in Nutrition With Adult Segment Leading Growth
ABT Nutrition unit posts steady gains as adult-focused brands like Ensure and Glucerna drive global demand and market share growth.
Abbott Taps Growing TMVR Market With Tendyne System
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.
Abbott Laboratories Q2 Earnings: Dividends Don't Lie
Abbott's Q2 performance reflects some evenness and the potential headwinds from macroeconomic uncertainties. However, short-term issues like tariffs and drug price control do not fundamentally alter Abbott's long-term moat. As a dividend aristocrat, its fundamental and valuation risks are better gauged by its dividend payouts than accounting EPS.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott's Q2 Diabetes Care Sales Rise 19.6%: What's Backing It?
ABT's Diabetes Care sales surge 19.6% in Q2, fueled by strong U.S. demand and new OTC approvals for its CGM systems.
3 Dividend Growth Stocks That Will Deliver Meaty Returns After 5 Years
Sufficient earnings growth to continually increase dividends at a comfortably low payout ratio that also accommodates expansion capex is an excellent signal for strong upside potential.
Best Dividend Aristocrats For August 2025
Dividend Aristocrats are outperforming SPY in July but still trail year-to-date; select Aristocrats delivered double-digit gains and strong dividend growth. 47 of 69 Aristocrats raised dividends in 2025, with an average growth rate of 4.92% and more increases expected, signaling ongoing income reliability. My 'Promising Aristocrats' list, focused on undervaluation and projected total return, has outperformed both NOBL and SPY since late June.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield
If you wonder whether Abbott Laboratories NYSE: ABT is a good buy in Q2 2025, the answer is yes. The company's management, portfolio, cash flow, capital return, and pipeline are why.
